Population Pharmacokinetics of Edoxaban in Chinese Patients With Non-Valvular Atrial Fibrillation

Summary

Based on the population pharmacokinetic data of Chinese patients with atrial fibrillation, the study will evaluate the suitability of the ENGAGE Population Pharmacokinetics model of edoxaban in patients with atrial fibrillation in China, and build a predictive dose model of edoxaban that meets the characteristics of Chinese people. It can provide perfect individualized dosing plan improves clinical efficacy and reduces adverse drug reactions.

Timeline

Start

2022-03-30

Primary completion

2024-08-30

Completion

2024-10-30

Publications

• Deng Y, Dai S, Zhu S, Jiang J, Chai L, Liu Z, Qian X, Chong L, Hu S, Gao Y, Chen H, Su S, Hua L, Tian L. Edoxaban Population Pharmacokinetics in Chinese Patients with Nonvalvular Atrial Fibrillation: Model-Informed Dose Adjustment. Thromb Haemost. 2026 Feb 12. doi: 10.1055/a-2802-3641. Online ahead of print.

Drugs

Indications